European Journal of Medicinal Chemistry 2015-01-01

Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.

Wenbo Zhou, Anling Huang, Yong Zhang, Qingxiang Lin, Weikai Guo, Zihua You, Zhengfang Yi, Mingyao Liu, Yihua Chen

文献索引：Eur. J. Med. Chem. 96 , 269-80, (2015)

全文：HTML全文

摘要

Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of aryl-thiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future. Copyright © 2015 Elsevier Masson SAS. All rights reserved.